1WM
DCOY

1900 Wealth Management’s Decoy Therapeutics DCOY Stock Holding History

1900 Wealth Management’s Portfolio DCOY Stock Details DCOY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1
Closed -$20K – 260
2021
Q4 		$20K Hold
1
– – ﹤0.01% 241
2021
Q3 		$41K Hold
1
– – ﹤0.01% 215
2021
Q2 		$42K Buy
+1
New +$44.5K ﹤0.01% 214

Other funds holding DCOY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LNWWM
Laird Norton Wetherby Wealth Management San Francisco, California $2.45B AUM

1900 Wealth Management's DCOY Position: Q1 2022 in Review

1900 Wealth Management sold out of Decoy Therapeutics (DCOY) in Q1 2022, closing a stake of 1 share — an estimated $20K sold.

1900 Wealth Management first reported a position in DCOY in Q2 2021 and held it in 3 quarters. The position peaked at $42K in Q2 2021. 15 funds tracked by Wall St. Rank hold DCOY as of Q1 2022.

  • 1900 Wealth Management reported no remaining Decoy Therapeutics position as of Q1 2022 after selling out during the quarter.
  • 1900 Wealth Management sold 1 Decoy Therapeutics share in Q1 2022, an estimated $20K.
  • 1900 Wealth Management first reported a position in Decoy Therapeutics in Q2 2021 and held it in 3 quarters.
  • 1900 Wealth Management's Decoy Therapeutics position peaked at $42K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Decoy Therapeutics as of Q1 2022.

Based on 1900 Wealth Management's 13F filing for Q1 2022, filed 27 Apr 2022.